Belka C - Search Results

1

Radiotherapy with and without temozolomide in elderly patients with glioblastoma.

Niyazi M, Schwarz SB, Suchorska B, Belka C. Niyazi M, et al. Among authors: belka c. Strahlenther Onkol. 2012 Feb;188(2):154-9. doi: 10.1007/s00066-011-0026-7. Epub 2012 Jan 11. Strahlenther Onkol. 2012. PMID: 22231634

2

First experiences of radiation treatment planning with PET/CT.

Paulsen F, Scheiderbauer J, Eschmann SM, Brechtel K, Klein M, Pfannenberg C, Mondry A, Hehr T, Belka C, Bamberg M. Paulsen F, et al. Among authors: belka c. Strahlenther Onkol. 2006 Jul;182(7):369-75. doi: 10.1007/s00066-006-1451-x. Strahlenther Onkol. 2006. PMID: 16826354

3

Isobologram analysis of triple therapies.

Niyazi M, Belka C. Niyazi M, et al. Among authors: belka c. Radiat Oncol. 2006 Oct 17;1:39. doi: 10.1186/1748-717X-1-39. Radiat Oncol. 2006. PMID: 17044920 Free PMC article.

4

Counting colonies of clonogenic assays by using densitometric software.

Niyazi M, Niyazi I, Belka C. Niyazi M, et al. Among authors: belka c. Radiat Oncol. 2007 Jan 9;2:4. doi: 10.1186/1748-717X-2-4. Radiat Oncol. 2007. PMID: 17212832 Free PMC article.

5

Efficacy of a triple treatment with irradiation, agonistic TRAIL receptor antibodies and EGFR blockade.

Niyazi M, Marini P, Daniel PT, Humphreys R, Jendrossek V, Belka C. Niyazi M, et al. Among authors: belka c. Strahlenther Onkol. 2009 Jan;185(1):8-18. doi: 10.1007/s00066-009-1856-4. Epub 2009 Feb 18. Strahlenther Onkol. 2009. PMID: 19224142

6

Hypofractionated reirradiation for recurrent malignant glioma.

Henke G, Paulsen F, Steinbach JP, Ganswindt U, Isijanov H, Kortmann RD, Bamberg M, Belka C. Henke G, et al. Among authors: belka c. Strahlenther Onkol. 2009 Feb;185(2):113-9. doi: 10.1007/s00066-009-1969-9. Epub 2009 Feb 25. Strahlenther Onkol. 2009. PMID: 19240998

7

Efficacy of triple therapies including ionising radiation, agonistic TRAIL antibodies and cisplatin.

Niyazi M, Marini P, Daniel PT, Humphreys R, Jendrossek V, Belka C. Niyazi M, et al. Among authors: belka c. Oncol Rep. 2009 Jun;21(6):1455-60. doi: 10.3892/or_00000374. Oncol Rep. 2009. PMID: 19424623

8

Combination of the pro-apoptotic TRAIL-receptor antibody mapatumumab with ionizing radiation strongly increases long-term tumor control under ambient and hypoxic conditions.

Marini P, Budach W, Niyazi M, Junginger D, Stickl S, Jendrossek V, Belka C. Marini P, et al. Among authors: belka c. Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):198-202. doi: 10.1016/j.ijrobp.2009.04.038. Int J Radiat Oncol Biol Phys. 2009. PMID: 19695436

9

Combined treatment with lexatumumab and irradiation leads to strongly increased long term tumour control under normoxic and hypoxic conditions.

Marini P, Junginger D, Stickl S, Budach W, Niyazi M, Belka C. Marini P, et al. Among authors: belka c. Radiat Oncol. 2009 Oct 27;4:49. doi: 10.1186/1748-717X-4-49. Radiat Oncol. 2009. PMID: 19860913 Free PMC article.

10

Choline PET based dose-painting in prostate cancer--modelling of dose effects.

Niyazi M, Bartenstein P, Belka C, Ganswindt U. Niyazi M, et al. Among authors: belka c. Radiat Oncol. 2010 Mar 18;5:23. doi: 10.1186/1748-717X-5-23. Radiat Oncol. 2010. PMID: 20298546 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

665 results

Search Page

Filters